Amgen

Amgen’s moat rests on a combination of scale in biologics manufacturing, a broad portfolio of patent‑protected biologics and first‑in‑class therapies (e.g., Tezspire, Blincyto, Imdelltra), AND know‑how in clinical development and global commercialization. Biosimilars capabilities add a cost advantage and payer access benefits.

These advantages are durable, though less impregnable than true network effects. Q2 2025 saw 13% volume growth across the portfolio, underscoring franchise breadth despite price pressure.

Risks to moat durability include: denosumab biosimilar entry in 2025 that erodes Prolia/Xgeva; Otezla being on the 2027 Medicare negotiation list; Enbrel price pressure while U.S. exclusivity extends late into the decade; and competitive obesity incumbents.

On balance, multiple moderate moats outweigh single‑asset risk, but regulatory and biosimilar dynamics cap the score.